Trial Profile
An Open Label, Single-Period Repeated Dose Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Pitolisant, at Steady-State Conditions, in Healthy CYP2D6 Genotyped Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pitolisant (Primary)
- Indications Hypersomnia; Narcolepsy
- Focus Pharmacokinetics
- Sponsors Bioprojet
- 13 Oct 2016 New trial record